Skip to content
Review Open access

Current and future therapies for acute myeloblastic leukemia

Oct 2026 · Journal of Hematology & Oncology · Vol 19 · 0 citations · 190 references
Medicine

TL;DR

The role of intensive cytarabine plus anthracycline plus anthracycline-based regimens and venetoclax-based lower-intensity approaches are discussed, as well as targeted therapies directed against FLT3, IDH1/2, NPM1, and KMT2A-rearranged AML.

Abstract

The management of acute myeloid leukemia (AML) has undergone a remarkable transformation over the past decade, as advances in genomic profiling and drug development have expanded therapeutic options and enabled increasingly personalized treatment approaches. This review summarizes the evolving therapeutic landscape of AML, including current intensive and lower-intensity treatment backbones, approved molecularly targeted therapies, and emerging investigational strategies. We discuss the role of intensive cytarabine plus anthracycline-based regimens and venetoclax-based lower-intensity approaches, as well as targeted therapies directed against FLT3, IDH1/2, NPM1, and KMT2A-rearranged AML. We further examine efforts to optimize existing treatment paradigms through the incorporation of venetoclax into intensive chemotherapy, rational targeted combinations, and novel triplet regimens, in addition to the emerging use of highly active lower-intensity therapies in younger fit patients. Finally, we highlight promising future directions in AML, including therapies targeting RAS/MAPK signaling, emerging approaches for TP53-mutated disease, and immunotherapeutic strategies. AML treatment is rapidly evolving from broadly applied chemotherapy-based approaches toward increasingly molecularly informed and individualized therapeutic strategies. Continued advances in molecular diagnostics, targeted therapies, and synergistic combination regimens have the potential to further increase remission durability, reduce relapses, and improve long-term outcomes for patients with AML.

Read PDF

Similar papers

Review Open access Nov 2026

Chronic lymphocytic leukemia: recent advances and emerging therapeutic strategies

This review has synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL and examined the clinical efficacy reported in pivotal trials involving patients with relapsed/refractory CLL.

Jongheon Jung · 0 citations
Review Open access Oct 2026

Therapeutic strategies in the post-venetoclax era of acute myeloid leukemia

The therapeutic landscape of acute myeloid leukemia (AML) has changed substantially over the past decade with the incorporation of molecularly targeted agents, lower-intensity venetoclax-based regimens, and increasingly refined genetic risk stratification. Among these advances, the combination of venetoclax with hypome...

Huan Zhang, Shi-Jie Zhang, Jing-Xin Zhang · 0 citations
Review Open access Oct 2026

ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL THERAPIES: CHANGING INDICATIONS AND DYNAMIC RISK ASSESSMENT

Allogeneic HSCT remains a major potentially curative treatment for patients with AML at high risk of relapse. However, the rapid development of targeted agents and novel non-intensive therapies has substantially changed the therapeutic landscape, raising questions regarding the optimal timing and indications for transp...

Simona Sica, F. Frioni, M. Breccia et al. · 0 citations
Review Open access Sep 2026

Search for leukemia-restricted targets: a new paradigm for precision immunotherapy in acute myeloid leukemia.

Acute myeloid leukemia (AML) remains a major therapeutic challenge despite remarkable advances in genomic characterization. Although molecular profiling has transformed disease classification and risk stratification, treatment for most patients continues to rely on cytotoxic chemotherapy regimens developed more than 50...

S. Meshinchi, Franco Locatelli · 0 citations
Review Open access Sep 2026

Precision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic tools

It is proposed that the future of DLBCL management lies not merely in the availability of novel agents, but in the rational sequencing and combination of these modalities based on dynamic molecular monitoring and individualized risk assessment—translating molecular insights into actionable clinical pathways.

B. Guo, Hai-Ke Lei, Yao Liu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.